VanEck Biotech ETF (NASDAQ:BBH) Shares Sold by Assetmark Inc.

Assetmark Inc. cut its holdings in shares of VanEck Biotech ETF (NASDAQ:BBH) by 88.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 384 shares of the company’s stock after selling 3,081 shares during the period. Assetmark Inc.’s holdings in VanEck Biotech ETF were worth $60,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Strategic Financial Concepts LLC acquired a new stake in VanEck Biotech ETF in the 4th quarter valued at $3,828,000. Jane Street Group LLC boosted its holdings in VanEck Biotech ETF by 401.7% in the 3rd quarter. Jane Street Group LLC now owns 8,348 shares of the company’s stock worth $1,481,000 after buying an additional 6,684 shares during the last quarter. Janney Montgomery Scott LLC acquired a new stake in VanEck Biotech ETF in the 4th quarter worth about $481,000. Commonwealth Retirement Investments LLC acquired a new stake in VanEck Biotech ETF in the 4th quarter worth about $215,000. Finally, Wilmington Savings Fund Society FSB acquired a new stake in shares of VanEck Biotech ETF in the third quarter worth approximately $166,000. 32.05% of the stock is owned by institutional investors and hedge funds.

VanEck Biotech ETF Stock Up 1.0 %

Shares of BBH opened at $162.66 on Friday. The stock has a market cap of $396.89 million, a PE ratio of 30.97 and a beta of 0.85. VanEck Biotech ETF has a 52-week low of $151.35 and a 52-week high of $183.64. The firm’s fifty day moving average is $162.68 and its two-hundred day moving average is $167.77.

VanEck Biotech ETF Announces Dividend

The company also recently declared a dividend, which was paid on Tuesday, December 24th. Stockholders of record on Monday, December 23rd were given a dividend of $1.2517 per share. The ex-dividend date of this dividend was Monday, December 23rd.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.